Full Text
Cost Effectiveness of Ruxolitinib Versus Best Available Therapy For The Treatment of Myelofibrosis From Public Health Perspective In Chile

Abstract

Authors

R Rojas C Balmaceda C Vargas MA Espinoza

Back to Volume 19, Issue 7
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×